National Institute of Diabetes and Digestive and Kidney Diseases; Amended Notice of Meeting, 55858 [E8-22604]
Download as PDF
<![CDATA[
55858
Federal Register / Vol. 73, No. 188 / Friday, September 26, 2008 / Notices
jlentini on PROD1PC65 with NOTICES
individuals using influenza whole
genome phage display at
‘‘Immunobiology and Pathogenesis of
Influenza Infection’’, Atlanta: June 1–3,
2008. (poster presentation).
Patent Status: International Patent
Application PCT/US2008/067001 filed
13 Jun 2008 (HHS Reference No. E–236–
2007/3–PCT–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Kevin W. Chang,
Ph.D.; 301–435–5018;
changke@mail.nih.gov.
Collaborative Research Opportunity:
The FDA, Center for Biologics
Evaluation and Research (CBER),
Division of Viral Products, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize these peptides as vaccine
candidates or diagnostics. Please contact
Alice Welch at alice.welch@fda.hhs.gov
or 301–827–0359 for more information.
A Rapid Ultrasensitive Assay for
Detecting Prions Based on the Seeded
Polymerization of Recombinant Normal
Prion Protein (rPrP-sen)
Description of Technology: Prion
diseases are neurodegenerative diseases
of great public concern because humans
may be infected from hoofed animals
used as food, food products such as
milk, or blood products. Currently
available tests for disease-causing prions
are either incapable of detecting low
concentrations of prions and must be
used post-mortem or are incapable of
detecting low concentrations of prions
economically or accurately. This
technology enables rapid and
economical detection of sub-lethal
concentrations of prions by using
recombinant, normal, prion protein
(rPrP-sen) as a marker or indicator of
infectious prions in a sample.
Specifically, prions (contained in a
sample) seed the polymerization of
rPrP-sen, and polymerized rPrP-sen is
detected as an amplified indicator of
prions in the sample. This assay differs
from the protein-misfolding cyclic
amplification assay (PMCA) because it
enables the effective use of rPrP-sen and
does not require multiple amplification
cycles unless a higher degree of
sensitivity is required. It is anticipated
that this technology can be combined
with additional prion-detection
technologies to further improve the
sensitivity of the assay. In its current
embodiment, this assay has been used to
detect prions in brain tissue or cerebral
spinal fluid (CSF) from humans (variant
CJD), sheep (scrapie), and hamsters
(scrapie).
Advantages:
VerDate Aug<31>2005
18:07 Sep 25, 2008
Jkt 214001
• Uses a consistent, concentrated
source of normal prion protein (rPrPsen)
• Prions are detectable to low levels
after a single amplification round
• May be combined with
complimentary detection technologies
to improve sensitivity
• Demonstrated to be effective at
detecting prions from different species
• May be applicable to blood
products
• Economical
Applications:
• A test for live animals or food
products
• A human diagnostic for early
detection of prion diseases
• Monitor for effectiveness of
treatments or disease progression
Inventors: Byron W. Caughey,
Ryuichiro Atarashi, Roger A. Moore,
and Suzette A. Priola (NIAID).
Related Publications:
1. R Atarashi et al. Simplified
ultrasensitive prion detection by
recombinant PrP conversion with
shaking. Nat Methods 2008
Mar;5(3):211–212.
2. R Atarashi et al. Ultrasensitive
detection of scrapie prion protein using
seeded conversion of recombinant prion
protein. Nat Methods 2007
Aug;4(8):645–650.
Patent Status:
• PCT Application No. PCT/US2008/
070656 filed 21 Jul 2008 (HHS
Reference No. E–109–2007/1–PCT–01).
• U.S. Application No. 12/177,012
filed 21 Jul 2008 (HHS Reference No. E–
109–2007/1–US–02).
Licensing Status: Available for
exclusive and non-exclusive licensing.
Licensing Contact: RC Tang, JD, LLM;
301–435–5031; tangrc@mail.nih.gov.
Collaborative Research Opportunity:
The NIAID Laboratory of Persistent
Viral Diseases, TSE/Prion Biochemistry
Section, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. Please
contact Rosemary Walsh at 301–451–
3528 or rcwalsh@niaid.nih.gov.
Dated: September 18, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–22610 Filed 9–25–08; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases;
Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute of
Diabetes and Digestive and Kidney
Diseases Special Emphasis Panel,
October 17, 2008, 2:30 p.m. to 3:30 p.m.,
National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 which
was published in the Federal Register
on September 11, 2008, 73 FR 0177.
This meeting will be held October 22,
2008 instead of October 17, 2008. The
meeting is closed to the public.
Dated: September 18, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E8–22604 Filed 9–25–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Molecular Therapy
Core Centers.
Date: October 21, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Michele L. Barnard, PhD,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 753, 6707 Democracy Boulevard,
E:\FR\FM\26SEN1.SGM
26SEN1
]]>Agencies
[Federal Register Volume 73, Number 188 (Friday, September 26, 2008)]
[Notices]
[Page 55858]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-22604]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the National
Institute of Diabetes and Digestive and Kidney Diseases Special
Emphasis Panel, October 17, 2008, 2:30 p.m. to 3:30 p.m., National
Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard,
Bethesda, MD 20892 which was published in the Federal Register on
September 11, 2008, 73 FR 0177.
This meeting will be held October 22, 2008 instead of October 17,
2008. The meeting is closed to the public.
Dated: September 18, 2008.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E8-22604 Filed 9-25-08; 8:45 am]
BILLING CODE 4140-01-P
